OSE Pharma SA
Research OSE Pharma SA (OSE) on Bullrun: market cap EUR 78.42M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOSE
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 78.42M
- Financial periodFY2025
- RevenueEUR 2.62M
- Revenue growth-96.3%
- Net income-EUR 37.69M
- Free cash flow-EUR 34.13M
Valuation Snapshot
latest market cap is EUR 78.42M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 2.62M | -EUR 37.69M | -EUR 34.13M | n/a | -1.69 | EUR 17.55M | EUR 35.38M | EUR 27.76M |
| FY2024 | EUR 69.88M | EUR 37.45M | EUR 48.36M | n/a | 1.46 | EUR 16.75M | EUR 46.13M | EUR 63.81M |
| FY2023 | EUR 2.23M | -EUR 23.00M | -EUR 19.78M | n/a | -1.18 | EUR 18.67M | EUR 45.80M | EUR 22.98M |
| FY2022 | EUR 18.30M | -EUR 17.76M | -EUR 18.53M | n/a | -0.96 | EUR 25.62M | EUR 44.79M | EUR 32.66M |
| FY2021 | EUR 26.31M | -EUR 16.85M | -EUR 10.39M | n/a | -0.93 | EUR 33.58M | EUR 37.13M | EUR 47.89M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | EUR 78.42M | n/a | n/a | n/a |
About OSE Pharma SA
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. The company's products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is OSE Pharma SA's market cap?
OSE Pharma SA's market capitalization is EUR 78.42M.
What does OSE Pharma SA do?
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.